STAT+: Tortugas Neuroscience launches with hopes to develop drugs for brain disorders, other conditions
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tortugas Neuroscience secures $106 M from Cure Ventures, The Column Group, and AN Ventures to launch mid‑stage U.S. trials.
- Jiangsu Hansoh Pharmaceutical Group licenses two brain‑disorder drugs—one for schizophrenia, one for tinnitus—to Tortugas.
- Eisai Co. Ltd provides two additional candidates targeting focal epilepsy and encephalopathies for testing.
- Cure Ventures leads the investment round, marking its entry into neuroscience‑focused biotech ventures.
- Mid‑stage trials are slated to begin in the United States later this year, accelerating the path to market for the four drugs.
Why it matters: Tortugas Neuroscience and its $106M investors secure a foothold in US mental‑health drug development, while Chinese and Japanese partners gain a pathway to the American market, speeding cross‑border biotech collaboration.
Ask SkimNews
